Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biomed Pharmacother ; 159: 114167, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36621145

RESUMO

BACKGROUND: Monocytes play a large role in chronic inflammatory conditions such as obesity, atherosclerosis and infection. Marine-derived omega-3 fatty acids such as docosahexaenoic acid (DHA) beneficially alter immune function and attenuate chronic inflammation in part by modifying gene expression. Comparisons with plant-derived omega-3 α-linolenic acid (ALA) on immune cell gene expression and function are limited. METHODS: Transcriptome analysis was performed on THP-1 human monocytes treated with ALA, DHA or vehicle for 48 hr using fold change analysis, principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), variable importance analysis (VIP), and ingenuity pathway analysis (IPA). Candidate genes were validated by qPCR. Functional assays evaluated the transcriptomic predictions. Expression of candidate transcripts identified in THP-1 cells were examined in PBMC from clinical trial (OXBIO; NCT03583281) participants consuming ALA- or DHA-rich oil supplements. FINDINGS: ALA and DHA-treated monocytes presented distinct transcriptomic profiles as per VIP and PLS-DA. Both fatty acids were predicted to reduce cellular cholesterol content, while ALA would uniquely increase response to infection and chemotactic signals. Functional assays revealed ALA and DHA decreased cholesterol content. DHA significantly decreased the response to infection and chemotaxis, but ALA had no effect. Candidate transcripts responded similarly in PBMC from n-3 PUFA supplemented women with obesity. CONCLUSION: ALA and DHA differentially alter the transcription profiles and functions associated with the response to infection, chemotaxis, and cholesterol metabolism in mononuclear immune cells. Thus, they may uniquely affect related disease processes contributing to obesity, atherosclerosis, and the response to infection.


Assuntos
Aterosclerose , Ácidos Graxos Ômega-3 , Feminino , Humanos , Ácido alfa-Linolênico/farmacologia , Colesterol , Ácidos Docosa-Hexaenoicos/farmacologia , Ácidos Docosa-Hexaenoicos/metabolismo , Ácido Eicosapentaenoico , Ácidos Graxos Ômega-3/farmacologia , Leucócitos Mononucleares/metabolismo , Monócitos/metabolismo , Obesidade/tratamento farmacológico , Ensaios Clínicos como Assunto
2.
Artigo em Inglês | MEDLINE | ID: mdl-34051428

RESUMO

INTRODUCTION: Consumption of omega-3 polyunsaturated fatty acids (n-3 PUFAs) has been reported to provide health benefits, but it remains unknown whether the fatty acids themselves or their oxygenated metabolites, oxylipins, are responsible for the beneficial effects. PURPOSE: This paper describes the design and rationale of a randomized, double-blinded, cross-over study comparing the effects of α-linolenic acid (ALA)-rich flax oil and docosahexaenoic acid (DHA)-rich fish oil supplementation on circulating oxylipin profiles in females with obesity, in relation to obesity-induced inflammation. METHODS AND ANALYSIS: Pre-menopausal females (n = 24) aged 20-55 with a BMI ≥30, will consume capsules containing flaxseed oil (4 g ALA/day) or fish oil (4 g DHA + 0.8 g EPA/day) during 4-week supplementation phases, with a minimum 4-week washout. The primary outcome is alterations in plasma oxylipin profiles. Secondary outcomes include effects of supplementation on circulating markers of inflammation, adipokines, plasma fatty acid composition, blood lipid profile, anthropometrics, oxylipin and cytokine profiles of stimulated immune cells, monocyte glucose metabolism, blood pressure and pulse wave velocity. ETHICS AND SIGNIFICANCE: This trial has been approved by the University of Manitoba Biomedical Research Ethics Board and the St. Boniface Hospital Research Review Committee. The study will provide information regarding the effects of ALA and DHA supplementation on oxylipin profiles in obese but otherwise healthy females. Additionally, it will improve our understanding of the response of circulating inflammatory mediators originating from immune cells, adipose tissue and the liver to n-3 PUFA supplementation in relation to the metabolic features of obesity.


Assuntos
Ácidos Docosa-Hexaenoicos/uso terapêutico , Óleos de Peixe/uso terapêutico , Inflamação/metabolismo , Óleo de Semente do Linho/uso terapêutico , Obesidade/tratamento farmacológico , Oxilipinas/metabolismo , Ácido alfa-Linolênico/uso terapêutico , Adipocinas/metabolismo , Adulto , Glicemia/metabolismo , Estudos Cross-Over , Citocinas/metabolismo , Suplementos Nutricionais , Método Duplo-Cego , Ácidos Graxos Ômega-3 , Feminino , Humanos , Pessoa de Meia-Idade , Obesidade/metabolismo , Ensaios Clínicos Controlados Aleatórios como Assunto , Adulto Jovem
3.
Int J Biochem Cell Biol ; 119: 105662, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31811954

RESUMO

Alternatively activated macrophages are innate immune cells that contribute to resolution of inflammation and maintenance of homeostasis. Modulation of available fatty acid sources is thought to affect cellular physiology through a variety of mechanisms, including through alterations to the profile of oxygenated free fatty acid metabolites, called oxylipins, produced in a cell type specific manner. Here, we investigated how treatment with the plant-sourced omega-3 fatty acid α-linolenic acid (ALA) affects the oxylipin profile and functional capacity of a cell culture model of human alternatively activated (M2a-like) macrophages. In a targeted but unbiased screen, ALA enhanced the production of oxylipins from all polyunsaturated fatty acid (PUFA) precursors, with oxylipins derived from ALA being enhanced the most. Consistently, ALA treatment enhanced the expression of both cytoplasmic and calcium-independent phospholipase A2. At a functional level, ALA treatment increased phagocytic activity and altered production of the chemokine MCP-1 by M2a-like cells in a manner dependent on the time of treatment. ALA treatment during polarization increased MCP-1 secretion, which was sensitive to pharmacological inhibition of 15-LOX-1 by ML351. Thus, ALA modulates the phenotype of alternatively activated macrophages, likely through its own LOX-derived oxylipins and/or through general modulation of oxylipin biosynthesis. These effects likely contribute to the overall anti-inflammatory benefit observed with ALA supplementation.


Assuntos
Ativação de Macrófagos/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , Oxilipinas/metabolismo , Ácido alfa-Linolênico/farmacologia , Araquidonato 15-Lipoxigenase/imunologia , Araquidonato 15-Lipoxigenase/metabolismo , Quimiocina CCL2/metabolismo , Citocinas/imunologia , Citocinas/metabolismo , Humanos , Lipopolissacarídeos/farmacologia , Inibidores de Lipoxigenase/farmacologia , Macrófagos/imunologia , Macrófagos/metabolismo , Oxilipinas/imunologia , Fagocitose/efeitos dos fármacos , Fosfolipases A2/metabolismo , Células THP-1
4.
J Nutr Biochem ; 57: 121-129, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29698923

RESUMO

Chronic inflammation, mediated in large part by proinflammatory macrophage populations, contributes directly to the induction and perpetuation of metabolic diseases, including obesity, insulin resistance and type 2 diabetes. Polyunsaturated fatty acids (PUFAs) can have profound effects on inflammation through the formation of bioactive oxygenated metabolites called oxylipins. The objective of this study was to determine if exposure to the dietary omega-3 PUFA α-linolenic acid (ALA) can dampen the inflammatory properties of classically activated (M1-like) macrophages derived from the human THP-1 cell line and to examine the accompanying alterations in oxylipin secretion. We find that ALA treatment leads to a reduction in lipopolysaccharide (LPS)-induced interleukin (IL)-1ß, IL-6 and tumor necrosis factor-α production. Although ALA is known to be converted to longer-chain PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), DHA oxylipins were reduced overall by ALA treatment, as was LPS-induced secretion of EPA oxylipins. In contrast, we observed profound increases in oxylipins directly derived from ALA. Lipoxygenase products of linoleic acid were also dramatically increased, and LPS-induced production of AA oxylipins, particularly prostaglandin D2, was reduced. These results suggest that ALA may act to dampen the inflammatory phenotype of M1-like macrophages by a unique set of mechanisms distinct from those used by the long-chain omega-3 fatty acids EPA and DHA. Thus, there is strong rationale for investigating the functions of ALA oxylipins and lesser-known LA oxylipins since they hold promise as anti-inflammatory agents.


Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Ácido Linoleico/farmacologia , Macrófagos/efeitos dos fármacos , Oxilipinas/metabolismo , Ácido alfa-Linolênico/farmacologia , Anti-Inflamatórios não Esteroides/farmacocinética , Linhagem Celular , Polaridade Celular/efeitos dos fármacos , Sistema Enzimático do Citocromo P-450/metabolismo , Citocinas/metabolismo , Humanos , Ácido Linoleico/farmacocinética , Lipopolissacarídeos/toxicidade , Macrófagos/metabolismo , Proteína-Lisina 6-Oxidase/metabolismo , Reprodutibilidade dos Testes , Ácido alfa-Linolênico/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...